These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

760 related items for PubMed ID: 1578910

  • 1. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.
    Cassileth PA, Andersen JW, Bennett JM, Harrington DP, Hines JD, Lazarus HM, Mazza JJ, McGlave PP, O'Connell MJ, Paietta E.
    Leukemia; 1992; 6 Suppl 2():116-9. PubMed ID: 1578910
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
    Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH.
    N Engl J Med; 1998 Dec 03; 339(23):1649-56. PubMed ID: 9834301
    [Abstract] [Full Text] [Related]

  • 4. Autologous bone marrow transplantation vs intensive chemotherapy in first complete remission: interim results of GOELAM study in AML.
    Harousseau JL, Pignon B, Dufour P, Ifrah N, Solary E, Abgrall JF, Milpied N, Desablens B, Guyotat D, Herve P.
    Leukemia; 1992 Dec 03; 6 Suppl 2():120-3. PubMed ID: 1578912
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
    Visani G, Lemoli R, Tosi P, Martinelli G, Testoni N, Ricci P, Motta M, Gherlinzoni F, Leopardi G, Pastano R, Rizzi S, Piccaluga P, Isidori A, Tura S.
    Bone Marrow Transplant; 1999 Sep 03; 24(5):467-72. PubMed ID: 10482929
    [Abstract] [Full Text] [Related]

  • 7. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
    Ravindranath Y, Chang M, Steuber CP, Becton D, Dahl G, Civin C, Camitta B, Carroll A, Raimondi SC, Weinstein HJ, Pediatric Oncology Group.
    Leukemia; 2005 Dec 03; 19(12):2101-16. PubMed ID: 16136167
    [Abstract] [Full Text] [Related]

  • 8. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR, Christiansen NP, Frankel SR, Brunetto VL, Mrózek K, Bloomfield CD, Herzig GP.
    Semin Oncol; 1993 Dec 03; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [Abstract] [Full Text] [Related]

  • 9. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Dec 03; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

  • 10. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Selleslag D, Zittoun R, Dardenne M.
    Leukemia; 1995 Nov 03; 9(11):1805-11. PubMed ID: 7475266
    [Abstract] [Full Text] [Related]

  • 11. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A, German AML Cooperative Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4496-504. PubMed ID: 14673036
    [Abstract] [Full Text] [Related]

  • 12. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
    Bassan R, Raimondi R, Lerede T, D'emilio A, Buelli M, Borleri G, Personeni A, Bellavita P, Rodeghiero F, Barbui T.
    Haematologica; 1998 Jul 15; 83(7):627-35. PubMed ID: 9718868
    [Abstract] [Full Text] [Related]

  • 13. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
    Bone Marrow Transplant; 1999 Feb 15; 23(3):235-41. PubMed ID: 10084254
    [Abstract] [Full Text] [Related]

  • 14. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
    Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G.
    N Engl J Med; 1995 Jan 26; 332(4):217-23. PubMed ID: 7808487
    [Abstract] [Full Text] [Related]

  • 15. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug 26; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 16. Long-term results in non randomized patients with acute myelogenous leukemia: a single institution experience.
    Deliliers GL, Annaloro C, Oriani A, Della Volpe A, Boschetti C, Cortelezzi A, Maiolo AT.
    Ann Ital Med Int; 1998 Aug 26; 13(3):146-51. PubMed ID: 9859570
    [Abstract] [Full Text] [Related]

  • 17. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
    Hübner G, Link H, Schönrock-Nabulsi P, Wandt H, Gramatzki M, Löffler B, Fackler-Schwalbe I, Queisser W, Brack N, Geer T, Raab M, Ohl S, Schneider B, Schneider C, Freund M, Poliwoda H, Ehninger G.
    Med Klin (Munich); 1996 Apr 12; 91 Suppl 3():26-32. PubMed ID: 8692115
    [Abstract] [Full Text] [Related]

  • 18. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
    Visani G, Lemoli RM, Isidori A, Piccaluga PP, Martinelli G, Malagola M, Gugliotta L, Bonini A, Bonifazi F, Motta MR, Rizzi S, Castellani S, Tura S.
    Bone Marrow Transplant; 2001 Apr 12; 27(8):829-35. PubMed ID: 11477440
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
    Michel G, Leverger G, Leblanc T, Nelken B, Baruchel A, Landman-Parker J, Thuret I, Bergeron C, Bordigoni P, Esperou-Bourdeau H, Perel Y, Vannier JP, Schaison G.
    Bone Marrow Transplant; 1996 Feb 12; 17(2):191-6. PubMed ID: 8640165
    [Abstract] [Full Text] [Related]

  • 20. Maintenance therapy in childhood acute myeloid leukemia.
    Perel Y, Auvrignon A, Leblanc T, Michel G, Vannier JP, Dalle JH, Gandemer V, Schmitt C, Mèchinaud F, Lamagnere JP, Piguet Ch, Couillaud G, Pautard B, Baruchel A, Leverger G, Group LAME, French Society of Pediatric Hematology and Immunology.
    Ann Hematol; 2004 Feb 12; 83 Suppl 1():S116-9. PubMed ID: 15124700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.